Tremelimumab
Modify Date: 2025-09-18 16:56:28
Tremelimumab structure
|
Common Name | Tremelimumab | ||
|---|---|---|---|---|
| CAS Number | 745013-59-6 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of TremelimumabTremelimumab (Ticilimumab) is a fully humanized monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research[1]. |
| Name | Tremelimumab |
|---|---|
| Synonym | More Synonyms |
| Description | Tremelimumab (Ticilimumab) is a fully humanized monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Tremelimumab (Ticilimumab) has a higher affinity for CTLA-4-Ig than for CD28-Ig and that the antibody is specific for cynomolgus monkeys and humans[1]. Tremelimumab does not bind to human leukocyte FcγR and does not trigger the release of cytokines avoiding the cytokine release syndrome, but increases the IL-2 production upon stimulation with the staphylococcal enterotoxin A in a concentration-dependent manner[1]. Tremelimumab enhances the IL-2 production in T-cells[1]. |
| References |
| Storage condition | 2-8°C |
|---|
| Ticilimumab |
| CP-675206 |